Scarica l'app Stockscreener
1.59
3.64%
-0.06
Dopo l'orario di chiusura:
1.59
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMEA Giù?
Forum
Previsione
Precedente Chiudi:
$1.65
Aprire:
$1.65
Volume 24 ore:
1.30M
Relative Volume:
0.93
Capitalizzazione di mercato:
$94.62M
Reddito:
-
Utile/perdita netta:
$-144.01M
Rapporto P/E:
-0.3965
EPS:
-4.01
Flusso di cassa netto:
$-113.02M
1 W Prestazione:
-11.17%
1M Prestazione:
-21.29%
6M Prestazione:
+0.00%
1 anno Prestazione:
-86.19%
Intervallo 1D:
$1.59
$1.69
Intervallo di 1 settimana:
$1.5706
$1.78
Portata 52W:
$1.2905
$12.85
Biomea Fusion Inc Stock (BMEA) Company Profile
Nome
Biomea Fusion Inc
Settore
Industria
Telefono
(650) 980-9099
Indirizzo
1599 INDUSTRIAL ROAD, SAN CARLOS
Confronta BMEA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.59 | 118.08M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-28 | Iniziato | Jefferies | Buy |
| 2025-06-03 | Ripresa | Piper Sandler | Overweight |
| 2024-10-09 | Iniziato | Edward Jones | Buy |
| 2024-09-27 | Aggiornamento | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | Aggiornamento | Truist | Hold → Buy |
| 2024-08-29 | Iniziato | CapitalOne | Overweight |
| 2024-06-11 | Downgrade | Truist | Buy → Hold |
| 2024-06-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-04-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-06 | Iniziato | Truist | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-06-26 | Downgrade | Jefferies | Buy → Hold |
| 2023-05-12 | Iniziato | Barclays | Overweight |
| 2023-03-29 | Reiterato | Oppenheimer | Outperform |
| 2023-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2023-02-24 | Iniziato | Citigroup | Buy |
| 2022-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-12 | Iniziato | H.C. Wainwright | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-05-11 | Iniziato | JP Morgan | Overweight |
| 2021-05-11 | Iniziato | Jefferies | Buy |
| 2021-05-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Biomea Fusion Inc Borsa (BMEA) Ultime notizie
Can Biomea Fusion Inc. stock rebound after recent weaknessFed Meeting & AI Powered Buy and Sell Recommendations - newser.com
Is Biomea Fusion Inc. stock trading at a premium valuation2025 Price Targets & Community Consensus Picks - newser.com
Published on: 2025-10-15 05:16:47 - newser.com
BMEABiomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights - ADVFN
Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights - ADVFN
Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28 - ADVFN
Biomea Fusion Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights - ADVFN
What institutional flow reveals about Biomea Fusion Inc.Product Launch & Fast Exit/Entry Strategy Plans - newser.com
H.C. Wainwright reiterates Buy rating on Biomea Fusion stock amid investor concerns By Investing.com - Investing.com Australia
How geopolitical tensions affect Biomea Fusion Inc. stockQuarterly Investment Review & Daily Oversold Bounce Ideas - newser.com
Real time pattern detection on Biomea Fusion Inc. stock2025 Market Trends & Fast Entry High Yield Stock Tips - newser.com
Can Biomea Fusion Inc. stock hit analyst price targetsJuly 2025 Recap & Fast Gain Swing Alerts - newser.com
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Biomea Fusion Inc. meeting your algorithmic filter criteriaJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
Biomea Fusion Inc. stock retracement – recovery analysisWeekly Trading Summary & Safe Entry Momentum Stock Tips - newser.com
Should you wait for a breakout in Biomea Fusion Inc.Portfolio Value Summary & Fast Exit and Entry Strategy Plans - newser.com
Biomea Fusion (NASDAQ:BMEA) Trading Up 6.5%What's Next? - MarketBeat
A Fresh Look at Biomea Fusion's (BMEA) Valuation Following Clinical Milestone and $25M Equity Raise - Sahm
Tools to assess Biomea Fusion Inc.’s risk profileMarket Sentiment Review & Technical Entry and Exit Alerts - newser.com
Biomea Fusion (NASDAQ:BMEA) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat
Does Biomea Fusion Inc. fit your quant trading model2025 Market Overview & Precise Swing Trade Entry Alerts - newser.com
What analysts say about Biomea Fusion Inc stockBollinger Bands Signals & Free Unmatched Market Gains - earlytimes.in
Why Biomea Fusion (BMEA) Is Up After Positive Diabetes Data and $25M Equity Raise – And What’s Next - Yahoo Finance
Biomea Fusion Announces Positive Phase II Study Results - MSN
Why Biomea Fusion (BMEA) Is Up on Promising Phase II Diabetes Data and What It Could Mean Next - simplywall.st
Nasdaq Tumbles 200 Points; Trilogy Metals Shares Spike Higher - Benzinga
Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups - insights.citeline.com
Biomea Fusion prices $25 million public offering of shares and warrants - Investing.com Nigeria
Biomea Fusion prices $25 million public offering of shares and warrants By Investing.com - Investing.com South Africa
Biomea’s ‘durable’ menin inhibitor advancing in hard-to-treat diabetes - BioWorld MedTech
Biomea Fusion: Surging On Data, Sinking On FundingI'm On The Sidelines - Seeking Alpha
Traders Purchase High Volume of Biomea Fusion Call Options (NASDAQ:BMEA) - MarketBeat
Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study - inkl
Dow Jumps Over 100 Points; McCormick Earnings Top Views - Benzinga
Biomea Fusion announces pricing of public offering of securities - MSN
Biomea Fusion plunges on $25 mln stock-and-warrants offering - TradingView
Biomea Fusion Announces Pricing of Public Offering of Securities - The Manila Times
D. Boral Capital Maintains Biomea Fusion (BMEA) Buy Recommendation - Nasdaq
$25M Offering: Biomea Fusion Prices 11.2M Shares & Warrants at $2.05 — Closing Oct 8, 2025 - Stock Titan
Biomea Fusion launches public offering of common stock and warrants - Investing.com India
Biomea Fusion announces proposed public offering of securities - MarketScreener
Biomea Fusion, Inc. (BMEA) Stock: Volatile Surge Ahead of Jefferies-Led Equity Offering - parameter.io
Biomea's diabetes drug shows promise, may work for those not responding to GLP-1 - MarketScreener
Biomea announces positive 52-week results from phase II COVALENT-111 study in type 2 diabetes - MarketScreener
Biomea Fusion Reports Phase 2 Data in Diabetes, Launches Stock Offering - MarketScreener
Biomea Fusion Announces Proposed Public Offering of Securities - GlobeNewswire
Biomea Fusion launches public offering of common stock and warrants By Investing.com - Investing.com Australia
Biomea Fusion reports 52-week results from Phase II diabetes trial - Investing.com
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Biomea Fusion Inc Azioni (BMEA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):